The Upjohn Co.

CRANBURY, N.J.--( BUSINESS WIRE )-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the appointment of Mikael Dolsten, M.D., Ph.D., as an independent director to its Board of Directors. Dr. Dolsten is an accomplished industry executive with extensive global pharmaceutical management experience. “ As an industry-leading pharmaceutical executive, I am very pleased to welcome Mikael to our Board of Directors,” said Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharma. “ His research and development experience will help advance our leading scientific capabilities and contribute to our mission of developing and delivering potentially transformative treatments for patients.” Throughout his career, Dr. Dolsten has held several positions and is currently the Chief Scientific Officer, President, Research & Development (R&D) at Pfizer Inc. (NYSE: PFE), focused on advancing gene therapies, small-molecule medicines, biotherapeutics, and vaccines. Dr. Dolsten’s previous roles include President of Research at Wyeth and Executive Vice President, Head of Worldwide Research at Boehringer Ingelheim, and senior R&D positions at AstraZeneca, Pharmacia, and Upjohn. He is a member of the Board of Overseers for the Scripps Research Institute and a Foreign Member of The Royal Swedish Academy of Engineering Sciences. He also advised the Obama administration on regulatory and drug development issues and then Vice President Biden’s Cancer Moonshot Initiative. “ Rocket has an impressive pipeline of clinical programs which have shown tremendous promise potentially curing genetic disease,” said Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development. “ I am excited to bring my passion and experience to Rocket as it becomes a commercial organization and strives to reach more patients in need.” About Rocket Pharmaceuticals, Inc. Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Rocket’s innovative multi-platform approach allows us to design the optimal gene therapy for each indication, creating potentially transformative options that enable people living with devastating rare diseases to experience long and full lives. Rocket’s lentiviral (LV) vector-based hematology portfolio consists of late-stage programs for Fanconi Anemia (FA), a difficult-to-treat genetic disease that leads to bone marrow failure (BMF) and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. Rocket’s adeno-associated viral (AAV) vector-based cardiovascular portfolio includes a late-stage program for Danon Disease, a devastating heart failure condition resulting in thickening of the heart, an early-stage program in clinical trials for PKP2-arrhythmogenic cardiomyopathy (ACM), a life-threatening heart failure disease causing ventricular arrhythmias and sudden cardiac death, and a pre-clinical program targeting BAG3-associated dilated cardiomyopathy (DCM), a heart failure condition that causes enlarged ventricles. For more information about Rocket, please visit www.rocketpharma.com and follow us on LinkedIn , YouTube, and X . Rocket Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements concerning Rocket’s future expectations, plans and prospects that involve risks and uncertainties, as well as assumptions that, if they do not materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this release are forward-looking statements. You should not place reliance on these forward-looking statements, which often include words such as “could,” “believe,” “expect,” “anticipate,” “intend,” “plan,” “will give,” “estimate,” “seek,” “will,” “may,” “suggest” or similar terms, variations of such terms or the negative of those terms. These forward-looking statements include, but are not limited to, statements concerning Rocket’s expectations regarding the safety and effectiveness of product candidates that Rocket is developing to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Danon Disease (DD) and other diseases, the expected timing and data readouts of Rocket’s ongoing and planned clinical trials, the expected timing and outcome of Rocket’s regulatory interactions and planned submissions, including the timing and outcome of the FDA’s review of the additional CMC information that Rocket will provide in response to the FDA’s request, the safety, effectiveness and timing of pre-clinical studies and clinical trials, Rocket’s ability to establish key collaborations and vendor relationships for its product candidates, Rocket’s ability to develop sales and marketing capabilities or enter into agreements with third parties to sell and market its product candidates, Rocket’s ability to expand its pipeline to target additional indications that are compatible with its gene therapy technologies, Rocket’s ability to transition to a commercial stage pharmaceutical company, and Rocket’s expectation that its cash, cash equivalents and investments will be sufficient to funds its operations into 2026. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket’s dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, unexpected expenditures, Rocket’s competitors’ activities, including decisions as to the timing of competing product launches, pricing and discounting, Rocket’s ability to develop, acquire and advance product candidates into, enroll a sufficient number of patients into, and successfully complete, clinical studies, the integration of new executive team members and the effectiveness of the newly configured corporate leadership team, Rocket’s ability to acquire additional businesses, form strategic alliances or create joint ventures and its ability to realize the benefit of such acquisitions, alliances or joint ventures, Rocket’s ability to obtain and enforce patents to protect its product candidates, and its ability to successfully defend against unforeseen third-party infringement claims, as well as those risks more fully discussed in the section entitled “Risk Factors” in Rocket’s Annual Report on Form 10-K for the year ended December 31, 2023, filed February 27, 2024 with the SEC and subsequent filings with the SEC including our Quarterly Reports on Form 10-Q. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Viatris completed the last of its $3.37bn divestitures, signing a deal with Cooper Consumer Health to transfer of its OTC business. Credit: SOPA Images via Getty Images. Viatris announced the finalisation of a transaction to divest its over-the-counter (OTC) business, completing the last step in its previously declared $3.37bn divestitures. The US-headquartered company divested its entire OTC business to Cooper Consumer Health, a European OTC drug manufacturer, on 3 July. In the agreement, Cooper Consumer Health has gained access to two manufacturing plants based in Merignac, France; and Confienza, Italy, and a research and development site in Monza, Italy. In its strategic plan, Viatris retained the rights for its blockbuster generic drugs Viagra (sildenafil) and Dymista (azelastine hydrochloride and fluticasone propionate) alongside certain other OTC therapies. Viatris first spread word of the OTC divestiture in October 2023 declaring definitive agreements to divest other areas of the company. Over the last few months, the nutraceutical company Matrix Pharma Private gained access to Viatris’ active pharmaceutical ingredients division and Spanish pharmaceutical company Insud Pharma acquired Viatris’ women’s health business. The latter deal gave Insud Pharma two manufacturing plants in India. Furthermore, a December 2023 definitive agreement transferred Viatris’ European rights for therapies such as Duphaston (Dydrogesterone) and Femoston (estradiol) to Theramex . The generics company also divested commercialisation rights in some non-core markets that were acquired, when Viatris was formed through the combination of Mylan and UpJohn. As per a 3 July press release, Viatris made the various divestitures to help achieve its “long-term gross leverage target” and “increase shareholder return through share buybacks and dividends”. The generics company also plans to use the money to acquire, develop and commercialise more therapies in the future. Last year, the company generated a total revenue of $15.4bn, reaching a free cash flow of $2.4bn. By 28 January 2024, the company had already completed $250m in share repurchases for this year. See Also: Left in limbo: When pharma halts rare disease research The pathway to preventative health: How pharma can support the NHS Long Term Plan In November 2022, Viatris released a strategic update detailing a two-stage plan for business growth with plans to end Phase I by the end of this year and execute Phase II between 2024 and 2028. In the first phase, the company aimed to complete all planned divestitures, have seven consecutive quarters of strong performance and continue progress on key science programmes among other things. At the January 2024 JP Morgan Healthcare Conference, Viatris announced that it had achieved its goals for Phase I and will be advancing to Phase II, which prioritises the growth of the company’s ophthalmology division and prevention of base business erosion.

生物制药行业在2023年第四季度展现的势头延续到了今年。 在该行业的前25家公司中，有18家实现了年收入增长，使得2024年第一季度几乎与去年最后一个季度相匹配，当时有21家顶级公司公布了销售额增长。此外，今年前三个月有九家公司实现了两位数的增长， 比上一个时期多了一家。再次成为主导的是GLP-1糖尿病和肥胖症药物的销售商。 尽管诺和诺德（Novo Nordisk）以22%的年收入增长退出了首位，礼来公司（Eli Lilly）却凭借28%的季度增长接管了第一名。礼来可能会保持一段时间的领先地位。上个月，GlobalData预测礼来的Mounjaro将超过诺和的Ozempic， 成为顶级血糖调节治疗药物，预计到2029年销售额将达到惊人的340亿美元。"Mounjaro的新颖双重机制不仅强调了其临床价值，还表明其有潜力成为其类别中的顶级销售药物，" GlobalData的制药分析师Eleni Tokali在一份声明中说。"Mounjaro预计的增长率标志着市场动态可能向礼来有利的方向转变。"尽管诺和的旧GLP-1药物以超过2比1的优势超过了礼来，但势头似乎在礼来这边。在第一季度，Ozempic创造了43亿美元的销售额，增长率为35%，而Mounjaro带来了18亿美元，是2023年第一季度的三倍。至于公司的肥胖症后续治疗，诺和的Wegovy带来了13亿美元，增长了107%，而礼来的Zepbound在其上市的第一个完整季度实现了5.17亿美元的销售额。尽管诺和22%的增长率使其在第一季度成为行业顶级公司之一，但这是从上一季度37%的高增长率下降的。诺和第一季度的653亿丹麦克朗（94亿美元）也略低于上一季度的659亿丹麦克朗。这是诺和自2022年第二季度以来的首次连续下降，表明公司扩大生产的速度不足以满足对司美格鲁肽的压倒性需求。公司希望通过从CDMO巨头Catalent收购三家工厂来解决这个问题。礼来的优势来自于它自身的生产挑战，这些挑战限制了其满足其糖尿病和肥胖症药物需求的能力。"由于不断增长的体积生产被不断增加的批发商积压订单和需求所淹没，预计Mounjaro和Zepbound都将继续保持供应紧张，"Third Bridge分析师Lee Brown最近写道。其他实现两位数增长的公司：其他七家公司（包括三家日本公司）在第一季度实现了两位数增长，尽管其中一些旁边有星号。武田药品工业的营收增长了25%，但大部分增长可以归因于公司向默克出售三种抗体药物偶联（ADC）治疗药物的45亿美元预付款。武田正在推迟这些款项并将其计入收入。去年由于这笔交易，武田将其2024年的收入预测提高了1000亿日元（6.62亿美元）。另一家日本公司安斯泰来在本季度的收入增长了17%，尽管部分增长可以归因于地理萎缩治疗药物Izervay。安斯泰来去年在公司历史上最大的并购交易中收购了这种药物，即以59亿美元收购了Iveric Bio。安进公司的销售从去年第一季度起增长了22%。但在该公司13亿美元的年收入增长中，9.14亿美元可以归因于公司收购Horizon Therapeutics获得的产品。实现主要有机两位数增长的公司有阿斯利康（17%）、Vertex（13%）、武田（10%）和诺华（10%）。AZ和Vertex也通过连续的收入增长6%和7%展示了它们的势头。阿斯利康得益于其一系列处于黄金时期的畅销产品，包括心脏病治疗药物Farxiga、罕见病药物Ultomiris和癌症治疗药物Calquence、Imfinzi和Tagrisso。Vertex继续凭借其囊性纤维化药物攀升，并为镰状细胞病基因疗法Casgevy的推出奠定基础。实现个位数增长的巨头：包括默克（9%）、GSK（6%）、百时美施贵宝（5%）、吉利德（5%）、梯瓦（4%）、赛诺菲（2%）、强生（2%）和艾伯维（1%）在内的几家生物制药行业巨头在第一季度实现了个位数收入增长。默克的增长与超级畅销药Keytruda的持续增长相一致，该药在本季度增长了20%，达到69亿美元。与此同时，HPV疫苗Gardasil增长了14%，达到22亿美元。这两种产品共占公司本季度159亿美元收入的58%。GSK和J&J在一年后展示了增长，这一年他们剥离了消费者健康部门，在行业趋势中，公司越来越专注于其处方药部门。吉利德5%的增长是在上一季度下降4%之后，主要得益于其肿瘤产品增长了18%，肝病产品组合增长了9%。在第一季度下降的七家公司：在第一季度销售额下降的公司中，新出现的意外成员是再生元，尽管Dupixent持续增长，但下降了1%。这家纽约生物技术公司的下降主要是由于眼病治疗药物Eylea的销售下降。该公司的Eylea合作伙伴拜耳在同一时期也下降了3%，延续了这家陷入困境的德国公司的趋势，该公司正在CEO Bill Anderson的领导下进行大规模重组。季度销售额下降了19%，辉瑞是本季度唯一一家持续两位数下降的公司。当然，下降是由于对其COVID产品的需求下降。该公司表示，这种影响现在应该已经过去了。对辉瑞来说，有很多积极的数字，其149亿美元的收入比分析师共识高出10亿美元。这也是辉瑞连续第三个季度实现收入增长。不包括COVID产品的销售，公司在最近一个季度增长了11%。另外两家在本季度销售额下降的公司——罗氏（6%）和默克（5%）——也将原因归咎于COVID产品和相关服务的收入损失。尽管眼病治疗药物Vabysmo的销售额飙升，迅速从Eylea那里夺取市场份额，罗氏的下降还是出现了。其他收入下降的公司包括Biogen（7%）和Viatris（2%）。由于其多发性硬化症产品的销售额下降，Biogen看到这一趋势在2024年继续，因为它预测这将是连续第五年年度收入下降。Viatris的下降也反映了公司的总体趋势，该公司自2021年由仿制药巨头Mylan和Upjohn合并成立以来，每年都在下降。识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。